PI-103
PI-103 (CAS 371935-74-9) is a selective inhibitor of class I phosphatidylinositol 3-kinases (PI3Ks), mechanistic target of rapamycin (mTOR), and DNA-dependent protein kinase (DNA-PK). It suppresses activity of p110α, p110β, p110δ, p110γ, mTOR, and DNA-PK, with IC50 values of 2, 3, 3, 15, 30, and 23 nM, respectively. PI-103 inhibits proliferation across multiple cancer cell lines, including glioblastoma, ovarian, and prostate cancers. It effectively reduces phosphorylation levels of AKT, GSK3β, p70S6K, and S6RP, thereby rendering it useful for studying PI3K/mTOR signaling pathways in oncology research.
References:
[1]. Jed Pheneger, Eli Wallace, Allison Marlow, Brian Hurley, Joe Lyssikatos, Alison M. Bendele, Patrice A. Lee1. Array BioPharma, Boulder, CO; Bolder BioPath, Boulder, CO. Characterization of ARRY-438162, a potent MEK inhibitor in combination with Methotrexate or Ibuprofen in vivo models of arthritis. American college of rheumatology. 2006 Annual Scientific Meeting.
[2]. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, Bastian BC. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2013 Oct 21.
[3]. Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014 Mar 4;13:45.
[4]. Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014 May 26. pii: mdu169.
- 1. Hao Sun, Zhazheng He, et al. "Polyoxyethylene tallow amine and glyphosate exert different developmental toxicities on human pluripotent stem cells-derived heart organoid model." Sci Total Environ. 2024 Mar 25:918:170675. PMID: 38316312
- 2. Sabha N, Volpatti JR, et al. "PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models." J Clin Invest. 2016 Sep 1;126(9):3613-25. PMID:27548528
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 348.36 |
| Cas No. | 371935-74-9 |
| Formula | C19H16N4O3 |
| Solubility | ≥21.9 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| Chemical Name | 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol |
| SDF | Download SDF |
| Canonical SMILES | Oc1cccc(-c(nc2N3CCOCC3)nc3c2[o]c2ncccc32)c1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment: [1] | |
|
Cell lines |
A549 and H460 cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
72 hours, 2 μM for A549 cells 0.5 μM for H460 cells |
|
Applications |
Incubation of A549 cells with 2 μM PI-103 for 72 h induced an ~60% reduction in cell number. In contrast to A549 cells, H460 cells were highly sensitive to low-dose PI-103. Treatment of H460 cells with 0.5 μM PI-103 for 72 h resulted in ~60% inhibition. Results showed that exposure of A549 and H460 cells to PI-103 with the indicated concentrations for 72 h induced growth inhibition in a dose-dependent manner. |
| Animal experiment: [2] | |
|
Animal models |
FVB/N wild type mice injected with 37-31E-F3 cells |
|
Dosage form |
Intraperitoneal injection, 10 mg/kg, daily |
|
Applications |
PI-103 treatment promoted a significant in vivo tumor growth compared with the DMSO treated mice. It was effective by partially inhibiting the Akt and S6 ribosomal protein phosphorylation. Tumors from PI-103-treated mice showed higher levels of cyclin D1 and more proliferating cells as indicated by the number of Ki67 positive cells. PI-103-treated tumors had the lowest apoptotic rate. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Zou Z Q, Zhang X H, Wang F, et al. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med, 2009, 24(1): 97-101. [2] López‐Fauqued M, Gil R, Grueso J, et al. The dual PI3K/mTOR inhibitor PI‐103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. International journal of cancer, 2010, 126(7): 1549-1561. |
|
| Description | PI-103 is a multi-targeted inhibitor of PI3K for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. | |||||
| Targets | p110α | p110β | p110δ | p110γ | mTOR | DNA-PK |
| IC50 | 2 nM | 3 nM | 3 nM | 15 nM | 30 nM | 23 nM |
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
